296 related articles for article (PubMed ID: 32507315)
1. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
Donnez O; Donnez J
Fertil Steril; 2020 Sep; 114(3):640-645. PubMed ID: 32507315
[TBL] [Abstract][Full Text] [Related]
2. Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study.
Donnez J; Donnez O; Brethous M; Bestel E; Garner E; Charpentier S; Humberstone A; Loumaye E
Reprod Biomed Online; 2022 Jan; 44(1):200-203. PubMed ID: 34799277
[TBL] [Abstract][Full Text] [Related]
3. Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration.
Donnez J; Donnez O; Tourniaire J; Brethous M; Bestel E; Garner E; Charpentier S; Humberstone A; Loumaye E
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945090
[TBL] [Abstract][Full Text] [Related]
4. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
Donnez J; Taylor HS; Taylor RN; Akin MD; Tatarchuk TF; Wilk K; Gotteland JP; Lecomte V; Bestel E
Fertil Steril; 2020 Jul; 114(1):44-55. PubMed ID: 32505383
[TBL] [Abstract][Full Text] [Related]
5. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas.
Gracia M; Alcalà M; Ferreri J; Rius M; Ros C; Saco MA; Martínez-Zamora MÁ; Carmona F
J Minim Invasive Gynecol; 2018; 25(7):1274-1280. PubMed ID: 29626678
[TBL] [Abstract][Full Text] [Related]
6. Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists.
Donnez J; Stratopoulou CA; Dolmans MM
Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639243
[TBL] [Abstract][Full Text] [Related]
7. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
8. Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Conway F; Morosetti G; Camilli S; Martire FG; Sorrenti G; Piccione E; Zupi E; Exacoustos C
Gynecol Endocrinol; 2019 Mar; 35(3):207-210. PubMed ID: 30382803
[TBL] [Abstract][Full Text] [Related]
9. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
10. Regression of Adenomyosis on Magnetic Resonance Imaging after a Course of Hormonal Suppression in Adolescents: A Case Series.
Mansouri R; Santos XM; Bercaw-Pratt JL; Dietrich JE
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):437-40. PubMed ID: 26233288
[TBL] [Abstract][Full Text] [Related]
11. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Dababou S; Garzon S; Laganà AS; Ferrero S; Evangelisti G; Noventa M; D'Alterio MN; Palomba S; Uccella S; Franchi M; Barra F
Expert Opin Investig Drugs; 2021 Sep; 30(9):903-911. PubMed ID: 34278887
[TBL] [Abstract][Full Text] [Related]
12. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study.
Guo Y; Duan H; Cheng J; Zhang Y
BJOG; 2017 Aug; 124 Suppl 3():7-11. PubMed ID: 28856862
[TBL] [Abstract][Full Text] [Related]
13. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats.
Tezuka M; Tsuchioka K; Kobayashi K; Kuramochi Y; Kiguchi S
Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):610-617. PubMed ID: 37186405
[TBL] [Abstract][Full Text] [Related]
14. A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.
Pohl O; Baron K; Riggs M; French J; Garcia R; Gotteland JP
Br J Clin Pharmacol; 2022 May; 88(5):2359-2371. PubMed ID: 34904270
[TBL] [Abstract][Full Text] [Related]
15. Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials.
Donnez J; Donnez O; Dolmans MM
Fertil Steril; 2023 Nov; 120(5):1071-1073. PubMed ID: 37495010
[No Abstract] [Full Text] [Related]
16. Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
Tezuka M; Tamai Y; Kuramochi Y; Kobayashi K; Fushimi N; Kiguchi S
Clin Exp Pharmacol Physiol; 2022 Oct; 49(10):1082-1093. PubMed ID: 35690889
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis?
Borini A; Coticchio G
Fertil Steril; 2020 Sep; 114(3):517-518. PubMed ID: 32762949
[No Abstract] [Full Text] [Related]
18. Linzagolix: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1317-1325. PubMed ID: 35997940
[TBL] [Abstract][Full Text] [Related]
19. Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis.
Yang X; Zhang X; Lin B; Feng X; Aili A
Int J Hyperthermia; 2019; 36(1):486-492. PubMed ID: 30994010
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system.
Fong YF; Singh K
Contraception; 1999 Sep; 60(3):173-5. PubMed ID: 10640162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
